-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Head-To-Head Review: Longview Acquisition Corp. II (NYSE:LGV) Vs. SANUWAVE Health (OTCMKTS:SNWV)
Head-To-Head Review: Longview Acquisition Corp. II (NYSE:LGV) Vs. SANUWAVE Health (OTCMKTS:SNWV)
Longview Acquisition Corp. II (NYSE:LGV – Get Rating) and SANUWAVE Health (OTCMKTS:SNWV – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, valuation, earnings, risk and dividends.
Risk and Volatility
Longview Acquisition Corp. II has a beta of 0.04, suggesting that its stock price is 96% less volatile than the S&P 500. Comparatively, SANUWAVE Health has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500.
Get Longview Acquisition Corp. II alerts:Analyst Recommendations
This is a summary of current ratings and price targets for Longview Acquisition Corp. II and SANUWAVE Health, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Longview Acquisition Corp. II | 0 | 0 | 0 | 0 | N/A |
SANUWAVE Health | 0 | 0 | 0 | 0 | N/A |
Valuation and Earnings
This table compares Longview Acquisition Corp. II and SANUWAVE Health's top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Longview Acquisition Corp. II | N/A | N/A | $7.40 million | N/A | N/A |
SANUWAVE Health | $13.01 million | 1.68 | -$27.26 million | N/A | N/A |
Longview Acquisition Corp. II has higher earnings, but lower revenue than SANUWAVE Health.
Institutional and Insider Ownership
66.3% of Longview Acquisition Corp. II shares are owned by institutional investors. 26.4% of Longview Acquisition Corp. II shares are owned by insiders. Comparatively, 16.4% of SANUWAVE Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Longview Acquisition Corp. II and SANUWAVE Health's net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Longview Acquisition Corp. II | N/A | -65.52% | 3.65% |
SANUWAVE Health | -129.57% | N/A | -108.04% |
Summary
Longview Acquisition Corp. II beats SANUWAVE Health on 5 of the 8 factors compared between the two stocks.
About Longview Acquisition Corp. II
(Get Rating)
Longview Acquisition Corp. II does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company intends to focus on businesses in the healthcare, industrials, consumer, media, technology, and technology services sector. The company was incorporated in 2020 and is based in New York, New York.
About SANUWAVE Health
(Get Rating)
SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.
Receive News & Ratings for Longview Acquisition Corp. II Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longview Acquisition Corp. II and related companies with MarketBeat.com's FREE daily email newsletter.
Longview Acquisition Corp. II (NYSE:LGV – Get Rating) and SANUWAVE Health (OTCMKTS:SNWV – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, valuation, earnings, risk and dividends.
Longview Acquisition Corp.II(NYSE:LGV-GET Rating)和SANUWAVE Health(OTCMKTS:SNWV-GET Rating)都是小盤醫療公司,但哪一家更好?我們將根據兩家公司的機構持股、盈利能力、分析師建議、估值、收益、風險和股息等方面的實力進行比較。
Risk and Volatility
風險和波動性
Longview Acquisition Corp. II has a beta of 0.04, suggesting that its stock price is 96% less volatile than the S&P 500. Comparatively, SANUWAVE Health has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500.
Longview Acquisition Corp.II的貝塔指數為0.04,這表明其股價的波動性比標準普爾500指數低96%。相比之下,SANUWAVE Health的貝塔係數為0.33,這表明其股價的波動性比標準普爾500指數低67%。
Analyst Recommendations
分析師建議
This is a summary of current ratings and price targets for Longview Acquisition Corp. II and SANUWAVE Health, as provided by MarketBeat.
這是由MarketBeat提供的Longview Acquisition Corp.II和SANUWAVE Health的當前評級和目標價摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Longview Acquisition Corp. II | 0 | 0 | 0 | 0 | N/A |
SANUWAVE Health | 0 | 0 | 0 | 0 | N/A |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
朗維尤收購公司II | 0 | 0 | 0 | 0 | 不適用 |
SANUWAVE健康 | 0 | 0 | 0 | 0 | 不適用 |
Valuation and Earnings
估值和收益
This table compares Longview Acquisition Corp. II and SANUWAVE Health's top-line revenue, earnings per share (EPS) and valuation.
此表比較了Longview Acquisition Corp.II和SANUWAVE Health的營收、每股收益(EPS)和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Longview Acquisition Corp. II | N/A | N/A | $7.40 million | N/A | N/A |
SANUWAVE Health | $13.01 million | 1.68 | -$27.26 million | N/A | N/A |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
朗維尤收購公司II | 不適用 | 不適用 | 740萬美元 | 不適用 | 不適用 |
SANUWAVE健康 | 1301萬美元 | 1.68 | -2,726萬元 | 不適用 | 不適用 |
Longview Acquisition Corp. II has higher earnings, but lower revenue than SANUWAVE Health.
Longview收購公司II的收益高於SANUWAVE Health,但營收低於SANUWAVE Health。
Institutional and Insider Ownership
機構和內部人持股
66.3% of Longview Acquisition Corp. II shares are owned by institutional investors. 26.4% of Longview Acquisition Corp. II shares are owned by insiders. Comparatively, 16.4% of SANUWAVE Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Longview Acquisition Corp.II的66.3%股份由機構投資者持有。Longview Acquisition Corp.II的26.4%股份由內部人士持有。相比之下,SANUWAVE Health 16.4%的股份由內部人士持有。強大的機構持股表明,大型基金管理公司、捐贈基金和對衝基金相信,一家公司有望實現長期增長。
Profitability
盈利能力
This table compares Longview Acquisition Corp. II and SANUWAVE Health's net margins, return on equity and return on assets.
此表比較了Longview收購公司II和SANUWAVE Health的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
Longview Acquisition Corp. II | N/A | -65.52% | 3.65% |
SANUWAVE Health | -129.57% | N/A | -108.04% |
淨利潤率 | 股本回報率 | 資產回報率 | |
朗維尤收購公司II | 不適用 | -65.52% | 3.65% |
SANUWAVE健康 | -129.57% | 不適用 | -108.04% |
Summary
摘要
Longview Acquisition Corp. II beats SANUWAVE Health on 5 of the 8 factors compared between the two stocks.
Longview Acquisition Corp.II在比較兩隻股票的8個因素中有5個超過了SANUWAVE Health。
About Longview Acquisition Corp. II
關於Longview收購公司II
(Get Rating)
(獲取評級)
Longview Acquisition Corp. II does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company intends to focus on businesses in the healthcare, industrials, consumer, media, technology, and technology services sector. The company was incorporated in 2020 and is based in New York, New York.
Longview Acquisition Corp.II沒有重大業務。擬與一家或多家企業進行合併、資本換股、資產收購、股票購買、重組或類似的業務合併。該公司打算專注於醫療保健、工業、消費者、媒體、技術和技術服務部門的業務。該公司成立於2020年,總部設在紐約。
About SANUWAVE Health
關於SANUWAVE Health
(Get Rating)
(獲取評級)
SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.
SANUWAVE Health,Inc.是一家衝擊波技術公司,在美國和國際上研究、開發和商業化用於再生醫學和其他應用的非侵入性、高能和聲波衝擊波。它的衝擊波被用來產生一種生物反應,導致身體通過組織、肌肉骨骼和血管結構的修復和再生而自我癒合。該公司的鉛再生產品是用於治療糖尿病足部潰瘍的dermaPACE設備。其保健產品和候選產品組合激活了生物信號和血管生成反應,包括新的血管形成和微循環改善,這有助於恢復人體的正常癒合過程和再生。該公司還專注於將其脈衝聲學細胞表達技術應用於傷口癒合、整形外科、整形/美容和心臟疾病。此外,它還提供用於治療糖尿病足部潰瘍、壓瘡、靜脈性腿部潰瘍、深組織壓力性損傷和手術傷口的UltraMist、非接觸式和非熱式超聲波治療設備;以及用於治療肌腱疾病、急性和骨不連骨折的OroPACE系統。該公司成立於2005年,總部設在佐治亞州的蘇瓦尼。
Receive News & Ratings for Longview Acquisition Corp. II Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longview Acquisition Corp. II and related companies with MarketBeat.com's FREE daily email newsletter.
接受Longview收購公司的新聞和評級II Daily-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Longview Acquisition Corp.II和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧